Exicure Inc. announced positive topline results from a completed Phase 2 clinical trial evaluating burixafor (GPC-100) in combination with propranolol and granulocyte colony-stimulating factor (G-CSF) for mobilizing hematopoietic progenitor cells (HPCs) in patients with multiple myeloma undergoing autologous hematopoietic cell transplantation. The data, presented at the 2025 American Society of Hematology (ASH) Annual Meeting, showed that approximately 90% of participants achieved the primary endpoint of collecting ≥2 × 10⁶ CD34+ cells/kg within two leukapheresis sessions. The study reported a favorable safety profile and rapid mobilization kinetics, with peak peripheral CD34+ cell levels observed within one hour of burixafor administration.